The breath-actuated nebulizer (BAN) is a new respiratory device to deliver short-acting β-agonists to patients with asthma exacerbations. This pediatric convenience sample experimental study compares the BAN with conventional nebulizers and demonstrates that the BAN allows for shorter treatment times to achieve improved clinical asthma scores with less albuterol, shorter emergency department length of stay, and fewer hospitalizations.
National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (EPR-3-2007). Bethesda, MD: National Heart, Lung, and Blood Institute; 2007. NIH Publication No. 07-451.
2.
SabatoKWardPHawkW. Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department. Respir Care. 2011;56:761-770.
3.
BoscoARhemRDolovichM. In vitro estimations of in vivo jet nebulizer efficiency using actual and simulated tidal breathing patterns. J Aerosol Med. 2005;18:427-438.
4.
NikanderKBisgaardH. Impact of constant and breath-synchronized nebulization on inhaled mass of nebulized budesonide in infants and children. Pediatr Pulmonol. 1999;28:187-193.
5.
NikanderKTurpeinenMWollmerP. Evaluation of pulsed and breath-synchronized nebulization of budesonide as a means of reducing nebulizer wastage of drug. Pediatr Pulmonol. 2000;29:120-126.
6.
RauJAriARestrepoR. Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir Care. 2004;29:174-179.
